[Gemcitabine in peritoneal mesothelioma: a case report].
Malignant peritoneal mesothelioma is a rare tumor whose prognosis is poor. We report a case history of a 57-year old woman with large peritoneal masses and ascites refractory to several chemotherapeutic regimens. The patient benefited of a dramatic regression of disease with symptomatic improvement during chemotherapy with gemcitabine. Serum CA-125 values declined consensually to tumor regression. The duration of response was 12 months. The activity of gemcitabine in malignant mesothelioma has been already confirmed in phase II studies. Data are also available suggesting that better results can be obtained combining this agent with cisplatin, and a multicenter phase II study is now exploring the activity of this combination.
Amodio
A
A
Istituto Regina Elena per lo Studio e la Cura dei Tumori, Roma, Italia.
Crecco
M
M
Del Medico
P
P
Paoletti
G
G
Lopez
M
M
D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use*; D018394:CA-125 Antigen / Q000097:blood; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008654:Mesothelioma / Q000175:diagnosis / Q000188:drug therapy*; D008875:Middle Aged; D010534:Peritoneal Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D013997:Time Factors; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D018394:CA-125 Antigen; D003841:Deoxycytidine; D000093542:Gemcitabine